What is Epitel?
Epitel is a digital health company dedicated to developing a wearable, wireless EEG monitoring platform. Its core mission is to make seizure detection accessible, affordable, and reliable. The company achieved a significant milestone with FDA clearance for its REMI® product in 2021, enabling its use in hospital emergency rooms and critical care units. This clearance marks Epitel's transition from a development-stage entity to a commercial-stage provider of advanced neurological monitoring solutions.
How much funding has Epitel raised?
Epitel has raised a total of $12.6M across 2 funding rounds:
Debt
$98K
Series A
$12.5M
Debt (2021): $98K with participation from PPP
Series A (2022): $12.5M led by Medmountain Ventures, Dexcom, Wavemaker Three-Sixty Health, Salt Lake City Angels, Genoa Ventures, Catalyst Health Ventures, and OSF Ventures
Key Investors in Epitel
Medmountain Ventures
MedMountain Ventures is an early-stage healthcare investor focused on transformative technologies, providing capital and strategic support to companies in the medical field.
Dexcom
Dexcom is a leading medical technology company specializing in continuous glucose monitoring systems, known for its innovation in diabetes management technology.
Wavemaker Three-Sixty Health
Wavemaker Three-Sixty Health is a U.S. venture capital fund exclusively focused on early-stage healthcare startups, aiming to improve patient experiences and outcomes through disruptive innovations.
What's next for Epitel?
The recent major strategic investment signals Epitel's readiness to scale its operations and expand the reach of its REMI® platform. With FDA clearance already secured for critical care settings, the company is poised to enhance its market presence and potentially explore new applications for its EEG monitoring technology. Future growth will likely involve strengthening partnerships with healthcare providers, further refining the product's capabilities, and potentially seeking additional capital to fuel broader commercialization efforts and research into new diagnostic tools.
See full Epitel company page
